Jan 162024 CRISPR/Vertex gene editing drug cleared for beta-thalassemia Vertex Pharma (VRTX) announces FDA nod gene editing therapy, Casgevy, developed with CRISPR Therapeutics (CRSP) for beta-thalassemia (TDT).
